Advances in Hemophilia A: New Developments in Nonfactor Replacement Strategies for Hemophilia A

Learn about emicizumab and its impact on monitoring assays and surgical management in hemophilia A.
Michael Callaghan, MD
Stacy Croteau Headshot
Stacy E. Croteau, MD, MMS
person default
Cindy A. Leissinger, MD
Guy A. Young, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.70 MB
Released: December 5, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech

Related Content

Download this short slideset from Clinical Care Options (CCO) on the management of newly diagnosed and relapsed light-chain (AL) amyloidosis

Ankit Kansagra, MD Shaji K. Kumar, MD Vaishali Sanchorawala, MD Released: January 19, 2022

Downloadable PDF summary transcript of expert answers to questions on hemophilia A management, from Clinical Care Options (CCO)

Miguel A. Escobar, MD Mark Reding, MD Guy A. Young, MD Released: January 18, 2022

Downloadable summary slideset from a live ASH 2021 satellite symposium on optimizing outcomes in hemophilia A with factor and nonfactor therapy from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: December 21, 2021

Efficacy and safety in the ATLAS-INH trial of fitusiran for hemophilia A or B with inhibitors presented at ASH 2021, as reported by Clinical Care Options (CCO)

Released: December 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings